
  
    
      
        Background_NNP
        Rapid_NNP ,_, robust_JJ and_CC reversible_JJ induction_NN of_IN transgene_NN
        expression_NN would_MD significantly_RB facilitate_VB certain_JJ
        applications_NNS of_IN gene_NN therapy_NN and_CC the_DT study_NN of_IN cancer_NN
        biology_NN ._. Several_JJ inducible_JJ systems_NNS have_VBP been_VBN developed_VBN to_TO
        regulate_VB gene_NN expression_NN at_IN the_DT transcriptional_NN level_NN in_IN a_DT
        temporal_JJ and_CC quantitative_JJ manner_NN ._. [_NN 1_CD 2_CD 3_CD 4_CD ]_NN These_DT include_VBP
        systems_NNS based_VBN on_IN heat_NN shock_NN ,_, heavy_JJ metal_NN ion_NN ,_, tetracycline_NN ,_,
        steroid_NN ,_, or_CC ecdysone_NN hormone_NN induction_NN ._. For_IN in_IN vivo_NN
        applications_NNS ,_, tetracycline_NN ,_, steroid_NN ,_, rapamycin_NN and_CC ,_,
        ecdysone_NN responsive_JJ systems_NNS have_VBP been_VBN studied_VBN most_JJS and_CC in_IN
        recent_JJ years_NNS ._. Currently_RB the_DT most_RBS popular_JJ inducible_JJ system_NN
        is_VBZ based_VBN on_IN components_NNS of_IN the_DT tetracycline_NN resistance_NN
        operon_NN ,_, which_WDT has_VBZ seen_VBN use_NN in_IN both_DT tumors_NNS [_NN 2_CD 5_CD ]_NN as_RB well_RB
        as_IN transgenic_JJ animals_NNS ._. [_NN 6_CD ]_NN However_RB ,_, these_DT systems_NNS have_VBP
        limitations_NNS the_DT most_RBS important_JJ being_NN the_DT significant_JJ
        background_NN expression_NN ._. Recently_RB ,_, the_DT development_NN of_IN an_DT
        inducible_JJ system_NN based_VBN on_IN the_DT insect_NN steroid_NN ecdysone_NN and_CC
        the_DT nuclear_JJ receptor_NN that_IN mediates_NNS its_PRP$ effect_NN [_NN 7_CD ]_NN has_VBZ
        provided_VBN an_DT alternative_NN that_WDT may_MD circumvent_VB these_DT
        limitations_NNS ._. The_DT use_NN of_IN ecdysone_NN inducible_JJ transgene_NN
        expression_NN in_IN vitro_NN [_NN 8_CD 9_CD ]_NN and_CC in_IN transgenic_JJ mice_NNS [_NN 10_CD ]_NN
        has_VBZ recently_RB been_VBN demonstrated_VBN ._. The_DT use_NN of_IN this_DT system_NN in_IN
        vivo_NN has_VBZ several_JJ potential_JJ advantages_NNS over_IN other_JJ regulatory_JJ
        systems_NNS ._. The_DT ecdysone_NN hormones_NNS do_VBP not_RB affect_VB mammalian_JJ
        physiology_NN like_IN glucocorticoids_NNS or_CC progestins_NNS and_CC are_VBP not_RB
        known_VBN to_TO be_VB toxic_JJ or_CC teratogenic_JJ like_IN tetracycline_NN [_NN 11_CD ]_NN
        allowing_VBG their_PRP$ use_NN in_IN both_DT developmental_NN studies_NNS with_IN
        transgenic_JJ animals_NNS as_RB well_RB as_IN in_IN the_DT context_NN of_IN gene_NN
        therapy_NN and_CC tumor_NN biology_NN studies_NNS in_IN mature_VBP animals_NNS ._.
        The_DT popularity_NN of_IN the_DT ecdysone_NN inducible_JJ gene_NN switch_NN
        system_NN has_VBZ led_VBN us_PRP to_TO investigate_VB its_PRP$ characteristics_NNS as_IN a_DT
        regulator_NN of_IN transgene_NN expression_NN in_IN tumor_NN xenografts_NNS since_IN
        to_TO our_PRP$ knowledge_NN ,_, this_DT has_VBZ not_RB yet_RB been_VBN reported_VBN ._. Prior_RB to_TO
        evaluating_VBG this_DT in_IN vivo_NN ,_, we_PRP have_VBP thoroughly_RB examined_VBN the_DT
        kinetics_NNS of_IN this_DT switch_NN in_IN vitro_NN in_IN 2_CD different_JJ tumor_NN cell_NN
        lines_NNS using_VBG 2_CD different_JJ reporters_NNS in_IN order_NN to_TO evaluate_VB the_DT
        generality_NN of_IN these_DT observations_NNS ._. The_DT in_IN vivo_NN evaluation_NN
        was_VBD carried_VBN out_IN in_IN a_DT model_NN of_IN highly_RB aggressive_JJ murine_NN
        bladder_NN cancer_NN ,_, which_WDT has_VBZ previously_RB been_VBN used_VBN for_IN testing_NN
        various_JJ therapeutic_JJ interventions_NNS ._. [_NN 12_CD 13_CD ]_NN These_DT bladder_NN
        cell_NN lines_NNS were_VBD transfected_JJ with_IN a_DT novel_NN ecdysone_NN system_NN
        regulating_VBG the_DT expression_NN of_IN firefly_RB luciferase_NN and_CC then_RB
        injected_VBN subcutaneously_RB into_IN syngeneic_JJ hosts_NNS ._. Treatment_NNP of_IN
        the_DT animals_NNS with_IN ecdysone_NN analog_NN
        A_DT /_NN -_: (_( 3_CD -_: methoxy-_NN 2_CD -_: ethylbenzoyl_NN )_) -_: A_DT /_NN '_'' -_: (_( 3_CD ,_, 5_CD -_: dimethylbenzoyl_NN )_) -_: A_DT /_NN '_'' -_: tert-butyl_JJ
        hydrazine_NN (_( GS-E_NNP )_) was_VBD then_RB carried_VBN out_IN with_IN subsequent_JJ
        evaluation_NN of_IN in_IN vivo_NN gene_NN expression_NN ._. Our_PRP$ data_NNS suggests_VBZ
        that_IN in_IN vivo_NN induction_NN of_IN tumor_NN transgene_NN expression_NN is_VBZ
        feasible_JJ and_CC reversible_JJ using_VBG an_DT ecdysone_NN switch_NN and_CC opens_VBZ
        the_DT avenue_NN for_IN the_DT efficient_JJ functional_JJ characterization_NN of_IN
        many_JJ newly_RB discovered_VBN genes_NNS as_RB well_RB as_IN novel_NN gene_NN therapy_NN
        approaches_NNS ._.
      
      
        Results_NNS
        
          Derivation_NNP of_IN mouse_NN tumor_NN cell_NN lines_NNS containing_VBG a_DT
          novel_NN gene_NN regulatory_JJ mechanism_NN
          A_DT description_NN of_IN the_DT plasmids_NNS encoding_VBG the_DT two_CD
          components_NNS of_IN an_DT ecdysone_NN inducible_JJ transcription_NN
          activation_NN system_NN was_VBD reported_VBN previously_RB [_NN 14_CD ]_NN ._. The_DT
          plasmids_NNS pGAL_NN 4_CD -_: EcR_NNP and_CC pVP_NN 16_CD -_: mRXR_NN encode_NN proteins_NNS which_WDT
          heterodimerize_NN and_CC regulate_VB transcription_NN upon_IN the_DT
          addition_NN of_IN ecdysone_NN type_NN ligands_NNS (_( Figure_NN 1_CD A_DT )_) ._. Using_VBG
          these_DT plasmids_NNS as_IN a_DT starting_NN point_NN ,_, a_DT novel_NN indicator_NN of_IN
          the_DT inducible_JJ gene_NN expression_NN system_NN was_VBD constructed_VBN as_IN
          follows_VBZ ._. The_DT CMV_NNP promoter_NN and_CC enhancer_NN were_VBD removed_VBN from_IN
          the_DT mammalian_JJ expression_NN vector_NN pCI-neo_JJ (_( Promega_NNP )_) ._.
          Inserted_NNP in_IN its_PRP$ place_NN were_VBD five_CD copies_NNS of_IN the_DT GAL_NNP 4_CD
          binding_JJ site_NN followed_VBN by_IN the_DT minimal_JJ promoter_NN region_NN of_IN
          the_DT major_JJ late_JJ promoter_NN from_IN adenovirus_JJ (_( from_IN pG_NN 5_CD -_: luc_NN
          (_( Promega_NNP )_) )_) and_CC the_DT coding_VBG region_NN for_IN the_DT enhanced_VBN green_JJ
          fluorescent_NN protein_NN (_( EGFP_NNP )_) gene_NN (_( from_IN pEGFP-N_JJ 1_LS )_)
          (_( Clontech_NNP )_) ._. The_DT control_NN plasmid_NN ,_, pRL-TK_JJ (_( Promega_NNP )_) ,_,
          expresses_VBZ the_DT Renilla_NNP luciferase_NN gene_NN under_IN the_DT control_NN
          of_IN the_DT HSV_NNP thymidine_NN kinase_NN (_( TK_NNP )_) promoter_NN ._. This_DT plasmid_NN
          provides_VBZ constitutively_RB high_JJ gene_NN expression_NN and_CC we_PRP use_VBP
          it_PRP as_IN an_DT indicator_NN of_IN the_DT number_NN of_IN tumor_NN cells_NNS present_JJ
          in_IN the_DT tissue_NN samples_NNS harvested_VBN from_IN mice_NNS in_IN the_DT in_IN vivo_NN
          experiments_NNS ._.
          MBT-_NNP 2_CD cells_NNS ,_, a_DT mouse_NN urothelial_NN cancer_NN cell_NN line_NN ,_, or_CC
          Panc_NNP 02_CD ,_, a_DT mouse_NN ductal_NN adenocarcinoma_NN ,_, were_VBD transfected_JJ
          by_IN electroporation_NN with_IN a_DT mixture_NN of_IN the_DT four_CD plasmids_NNS ;_:
          the_DT two_CD components_NNS of_IN the_DT gene_NN expression_NN system_NN ,_,
          pVP_NN 16_CD -_: mRXR_NN and_CC pGAL_NN 4_CD -_: EcR_NNP ;_: the_DT indicator_NN and_CC selection_NN
          plasmid_NN ,_, pGAL_NN 4_CD -_: EGFP-SV_NNP 40_CD -_: neo_NN ;_: and_CC the_DT internal_JJ control_NN
          plasmid_NN ,_, pRL-TK_JJ ._. Stably_NNP transfected_JJ MBT-_NNP 2_CD cells_NNS were_VBD
          selected_VBN in_IN media_NNS containing_VBG 500_CD μg_NN /_NN ml_NN G_NNP 418_CD and_CC Panc_NNP 02_CD
          cells_NNS in_IN 700_CD μg_NN /_NN ml_NN G_NNP 418_CD for_IN three_CD weeks_NNS after_IN which_WDT there_EX
          were_VBD many_JJ large_JJ cell_NN colonies_NNS on_IN each_DT transfection_NN plate_NN ._.
          The_DT drug_NN resistant_JJ cells_NNS were_VBD harvested_VBN by_IN
          trypsinization_NN ,_, pooled_VBN ,_, and_CC cloned_VBN to_TO single_JJ cells_NNS by_IN
          limiting_VBG dilution_NN in_IN 96_CD well_RB plates_NNS ._. When_WRB colonies_NNS had_VBD
          grown_VBN in_IN a_DT subset_NN of_IN the_DT wells_NNS in_IN the_DT 96_CD well_RB plate_NN ,_,
          fresh_JJ media_NNS containing_VBG GS-E_NNP was_VBD added_VBN to_TO all_DT wells_NNS to_TO a_DT
          final_JJ GS-E_NNP concentration_NN of_IN 5_CD μM_NN ._. Cells_NNP were_VBD treated_VBN for_IN
          24_CD hours_NNS and_CC all_DT wells_NNS were_VBD visualized_JJ with_IN the_DT
          fluorescent_NN microscope_NN to_TO detect_VB EGFP_NNP expression_NN ._.
          At_IN least_JJS 96_CD clones_NNS of_IN MBT-_NNP 2_CD or_CC Panc_NNP 02_CD clones_NNS
          demonstrating_VBG fluorescence_NN were_VBD trypsinized_JJ and_CC expanded_VBN
          into_IN 24_CD well_RB plates_NNS ._. When_WRB the_DT clones_NNS had_VBD reached_VBN at_IN least_JJS
          50_CD %_NN confluence_NN in_IN the_DT 24_CD well_RB plate_NN ,_, GS-E_NNP was_VBD again_RB added_VBN
          to_TO 5_CD μM_NN to_TO verify_VB the_DT earlier_JJR observation_NN of_IN induced_VBN EGFP_NNP
          expression_NN ._. Four_CD clones_NNS of_IN each_DT cell_NN line_NN exhibiting_VBG high_JJ
          levels_NNS of_IN EGFP_NNP expression_NN were_VBD expanded_VBN for_IN further_JJ
          analysis_NN ._. Each_DT cell_NN line_NN was_VBD transiently_RB transfected_JJ with_IN
          1_CD μg_NN pFR-luc_JJ and_CC carrier_NN DNA_NNP ._. Luciferase_NNP activity_NN in_IN the_DT
          DMSO_NNP treated_VBD wells_NNS was_VBD similarly_RB low_JJ in_IN all_DT wells_NNS of_IN the_DT
          triplicates_NNS of_IN the_DT eight_CD transfections_NNS ._. After_IN treatment_NN
          with_IN 15_CD μM_NN GS-E_NNP ,_, three_CD of_IN the_DT four_CD MBT-_NNP 2_CD clonal_NN cell_NN
          lines_NNS had_VBD a_DT two-fold_JJ or_CC lower_JJR increase_NN in_IN luciferase_NN
          activity_NN ._. Clone_NNP #_# 2_CD had_VBD 8_CD ._. 4_CD -_: fold_VB higher_JJR luciferase_NN
          activity_NN with_IN GS-E_NNP treatment_NN ._. This_DT clone_NN ,_, designated_VBN
          MBT_NNP 2_CD +_NN RheoSwitch-_NNP 2_CD ,_, was_VBD used_VBN for_IN further_JJ development_NN ._. In_IN a_DT
          similar_JJ analysis_NN ,_, Panc_NNP 02_CD +_NN RheoSwitch-_NNP 3_CD and_CC -_: 4_CD demonstrated_VBN
          induction_NN levels_NNS of_IN 366_CD -_: and_CC 428_CD -_: fold_VB respectively_RB ._. No_DT
          significant_JJ change_NN in_IN the_DT Renilla_NNP luciferase_NN activity_NN was_VBD
          observed_VBN with_IN GS-E_NNP treatment_NN in_IN all_DT cell_NN lines_NNS ._.
        
        
          Stable_NNP introduction_NN of_IN inducible_JJ reporter_NN genes_NNS
          into_IN the_DT RHeoSwitch_NNP tumor_NN cell_NN lines_NNS
          The_DT MBT-_NNP 2_CD +_NN RHeoSwitch-_NNP 2_CD cell_NN line_NN containing_VBG the_DT
          RHeoSwitch_NNP expression_NN system_NN was_VBD used_VBN for_IN the_DT
          introduction_NN of_IN two_CD different_JJ reporter_NN gene_NN systems_NNS ._. The_DT
          plasmid_NN ,_, pG_NN 5_CD -_: luc_NN ,_, contains_VBZ the_DT GAL_NNP 4_CD response_NN element_NN
          expressing_VBG the_DT luc_NN +_NN gene_NN (_( Figure_NN 1_CD B_NNP )_) ._. The_DT vector_NN
          pGAL_NN 4_CD -_: SEAP_NNP containing_VBG the_DT GAL_NNP 4_CD response_NN element_NN and_CC the_DT
          coding_VBG region_NN for_IN the_DT SEAP_NNP protein_NN ,_, a_DT unique_JJ ,_, second_JJ
          reporter_NN gene_NN ,_, was_VBD also_RB used_VBN ._. Each_DT of_IN these_DT vectors_NNS was_VBD
          linearized_JJ and_CC co-transfected_JJ with_IN linearized_JJ pSV_NN 40_CD -_: Zeo_NNP
          by_IN electroporation_NN into_IN the_DT MBT-_NNP 2_CD +_NN RHeoSwitch-_NNP 2_CD cells_NNS ._.
          Cells_NNP were_VBD selected_VBN in_IN media_NNS containing_VBG 400_CD μg_NN /_NN ml_NN Zeocin_NNP
          until_IN colonies_NNS appeared_VBD in_IN each_DT of_IN the_DT plates_NNS ._. Zeocin_NNP
          resistant_JJ cells_NNS were_VBD trypsinized_JJ ,_, pooled_VBN ,_, and_CC single_JJ cell_NN
          cloned_VBN by_IN limited_JJ dilution_NN in_IN 96_CD well_RB plates_NNS ._. Aliquots_NNP of_IN
          the_DT pooled_VBN cells_NNS used_VBN for_IN cloning_VBG were_VBD also_RB plated_JJ in_IN
          triplicate_NN ,_, treated_VBN with_IN GS-E_NNP or_CC DMSO_NNP for_IN 24_CD hrs_NNS ._. Assays_NNP
          for_IN the_DT appropriate_JJ reporter_NN in_IN each_DT cell_NN pool_NN showed_VBD
          induction_NN ratios_NNS of_IN 17_CD -_: fold_VB for_IN the_DT luciferase_NN
          transfected_JJ cells_NNS and_CC 22_CD -_: fold_VB for_IN the_DT SEAP_NNP transfected_JJ
          cells_NNS ._. This_DT verified_VBN the_DT presence_NN of_IN the_DT GS-E_NNP inducible_JJ
          reporter_NN genes_NNS (_( luciferase_NN or_CC SEAP_NNP )_) in_IN the_DT cloned_VBN pool_NN of_IN
          cells_NNS ._.
          Clones_NNP were_VBD grown_VBN in_IN Zeocin_NNP containing_VBG media_NNS until_IN
          colonies_NNS appeared_VBD ._. Eighty-four_NNP luciferase_NN transfected_JJ
          clones_NNS and_CC 113_CD SEAP_NNP transfected_JJ clones_NNS were_VBD transferred_VBN
          from_IN the_DT 96_CD well_RB plates_NNS and_CC duplicate_VB wells_NNS of_IN each_DT were_VBD
          treated_VBN with_IN either_DT DMSO_NNP or_CC 15_CD μM_NN GS-E_NNP in_IN DMSO_NNP for_IN 24_CD
          hours_NNS ._. Each_DT pair_NN of_IN wells_NNS was_VBD assayed_JJ for_IN reporter_NN
          protein_NN activity_NN and_CC clones_NNS demonstrating_VBG basal_NN levels_NNS of_IN
          activity_NN in_IN the_DT DMSO_NNP treated_VBD sample_NN and_CC high_JJ levels_NNS in_IN
          the_DT GS-E_NNP sample_NN were_VBD further_RBR expanded_VBN for_IN additional_JJ
          testing_NN ._. These_DT cell_NN clones_NNS were_VBD plated_JJ in_IN a_DT six_CD well_RB
          plate_NN and_CC triplicate_NN wells_NNS were_VBD treated_VBN with_IN DMSO_NNP or_CC 15_CD
          μM_NN GS-E_NNP for_IN 48_CD hours_NNS ._. Luciferase_NNP clone_NN
          MBT-_NNP 2_CD +_NN RHeoSwitch-_NNP 2_CD +_NN luc-_NN 5_CD B_NNP 3_CD was_VBD chosen_VBN to_TO be_VB used_VBN for_IN a_DT
          more_RBR detailed_JJ analysis_NN of_IN the_DT properties_NNS of_IN the_DT gene_NN
          induction_NN system_NN ._.
          The_DT inducible_JJ reporter_NN gene_NN plasmids_NNS ,_, pG_NN 5_CD -_: luc_NN and_CC
          pGAL_NN 4_CD -_: SEAP_NNP ,_, were_VBD transfected_JJ into_IN the_DT Panc_NNP 02_CD +_NN RHeoSwitch-_NNP 3_CD
          and_CC -_: 4_CD cells_NNS and_CC stable_JJ transfectants_NNS were_VBD isolated_VBN as_IN
          they_PRP were_VBD into_IN the_DT MBT-_NNP 2_CD +_NN RHeoSwitch_NNP cells_NNS ._. Multiple_NNP
          Zeocin_NNP resistant_JJ cell_NN clones_NNS from_IN the_DT four_CD transfections_NNS
          (_( 36_CD Panc_NNP 02_CD +_NN RHeoSwitch-_NNP 3_CD +_NN luc_NN ,_, 75_CD Panc_NNP 02_CD +_NN RHeoSwitch-_NNP 4_CD +_NN luc_NN ,_,
          8_CD Panc_NNP 02_CD +_NN RHeoSwitch-_NNP 3_CD +_NN GAL_NNP 4_CD -_: SEAP_NNP ,_, 98_CD
          Panc_NNP 02_CD +_NN RHeoSwitch-_NNP 4_CD +_NN SEAP_NNP )_) were_VBD plated_JJ in_IN duplicate_VB and_CC
          treated_VBN with_IN DMSO_NNP or_CC 15_CD μM_NN GS-E_NNP ._. A_DT sample_NN of_IN clones_NNS with_IN
          basal_NN level_NN of_IN reporter_NN in_IN the_DT DMSO_NNP treated_VBD sample_NN and_CC
          the_DT highest_JJS level_NN of_IN reporter_NN in_IN the_DT GS-E_NNP treated_VBD sample_NN
          were_VBD selected_VBN to_TO be_VB expanded_VBN and_CC further_RBR tested_VBN ._.
          Multiple_NNP assays_NNS in_IN triplicate_NN on_IN the_DT GAL_NNP 4_CD -_: SEAP_NNP
          transfected_JJ clones_NNS gave_VBD induction_NN levels_NNS ranging_VBG from_IN
          118_CD -_: to_TO 551_CD -_: fold_VB for_IN the_DT best_JJS five_CD Panc_NNP 02_CD +_NN RHeoSwitch-_NNP 3_CD
          clones_NNS and_CC from_IN 52_CD -_: to_TO 486_CD -_: fold_VB for_IN the_DT best_JJS twelve_CD
          Panc_NNP 02_CD +_NN RHeoSwitch-_NNP 4_CD clones_NNS ._. Clones_NNP
          Panc_NNP 02_CD +_NN RHeoSwitch-_NNP 3_CD +_NN GAL_NNP 4_CD -_: SEAP-_NNP 5_CD and_CC -_: 8_CD and_CC
          Panc_NNP 02_CD +_NN RHeoSwitch-_NNP 4_CD +_NN GAL_NNP 4_CD -_: SEAP-_NNP 8_CD and_CC -_: 9_CD were_VBD used_VBN for_IN
          further_JJ characterization_NN ._. Multiple_NNP assays_NNS in_IN triplicate_NN
          on_IN the_DT pG_NN 5_CD -_: luc_NN transfected_JJ clones_NNS yielded_VBD induction_NN
          levels_NNS ranging_VBG from_IN 32_CD -_: to_TO 51_CD -_: fold_VB for_IN the_DT four_CD best_JJS
          Panc_NNP 02_CD +_NN RHeoSwitch-_NNP 3_CD clones_NNS and_CC from_IN 7_CD -_: to_TO 94_CD -_: fold_VB for_IN the_DT
          four_CD best_JJS Panc_NNP 02_CD +_NN RHeoSwitch-_NNP 4_CD clones_NNS ._. Clones_NNP
          Panc_NNP 02_CD +_NN RHeoSwitch-_NNP 3_CD +_NN luc-_NN 3_CD C_NNP 1_CD AND_CC -_: 1_CD B_NNP 1_CD and_CC
          Panc_NNP 02_CD +_NN RHeoSwitch-_NNP 4_CD +_NN luc-_NN 3_CD A_DT 1_CD and_CC -_: 4_CD B_NNP 3_CD were_VBD used_VBN for_IN
          further_JJ characterization_NN ._. These_DT clones_NNS do_VBP not_RB exhibit_VB the_DT
          high_JJ levels_NNS of_IN induced_VBN GFP_NNP expression_NN that_WDT was_VBD seen_VBN in_IN
          the_DT initial_JJ RHeoSwitch_NNP transfected_JJ cells_NNS ._. This_DT may_MD be_VB
          explained_VBN by_IN the_DT fact_NN that_IN they_PRP were_VBD selected_VBN on_IN the_DT
          basis_NN of_IN the_DT induction_NN level_NN of_IN the_DT reporter_NN gene_NN
          expression_NN ,_, however_RB ,_, contrary_JJ to_TO the_DT initial_JJ screen_NN ,_, the_DT
          level_NN of_IN induction_NN of_IN GFP_NNP was_VBD not_RB used_VBN as_IN a_DT selection_NN
          criteria_NNS and_CC cell_NN clones_NNS in_IN which_WDT the_DT expression_NN of_IN GFP_NNP
          has_VBZ variegated_JJ were_VBD isolated_VBN ._. A_DT summary_NN flowchart_NN of_IN the_DT
          cell_NN line_NN selection_NN and_CC characterization_NN is_VBZ shown_VBN in_IN
          figure_NN 2_CD ._.
        
        
          Characterization_NNP of_IN the_DT novel_NN gene_NN regulatory_JJ
          mechanism_NN in_IN vitro_NN
          Treatment_NNP of_IN luciferase_NN clone_NN 5_CD B_NNP 3_CD with_IN 15_CD μM_NN GS-E_NNP for_IN
          48_CD hours_NNS consistently_RB induced_VBN luciferase_NN levels_NNS from_IN near_IN
          background_NN with_IN only_RB DMSO_NNP added_VBD ,_, to_TO nearly_RB 150_CD -_: fold_VB
          (_( Table_NNP 1_LS )_) when_WRB adjusted_VBN for_IN non_NN specific_JJ R-L_NNP uc_NN induction_NN
          which_WDT was_VBD approximately_RB 1_CD ._. 2_CD fold_VB ._. In_IN order_NN to_TO understand_VB
          the_DT induction_NN kinetics_NNS of_IN the_DT inducible_JJ system_NN ,_, cell_NN
          clone_NN MBT-_NNP 2_CD +_NN RHeoSwitch-_NNP 2_CD +_NN luc-_NN 5_CD B_NNP 3_CD was_VBD treated_VBN with_IN GS-E_NNP
          and_CC cells_NNS were_VBD harvested_VBN at_IN different_JJ times_NNS to_TO determine_VB
          the_DT time_NN course_NN of_IN gene_NN induction_NN ._. At_IN each_DT time_NN point_NN ,_,
          the_DT control_NN and_CC treated_VBN cells_NNS were_VBD collected_VBN in_IN passive_JJ
          lysis_NNS buffer_NN and_CC dual_JJ luciferase_NN assays_NNS performed_VBN ._. Data_NNP
          were_VBD plotted_VBD as_IN a_DT GS-E_NNP (_( RLU_NNP 1_CD /_NN RLU_NNP 2_LS )_) /_NN Control_NNP (_( RLU_NNP 1_CD /_NN RLU_NNP 2_LS )_)
          ratio_NN (_( as_IN in_IN Table_NNP 1_LS )_) fold_VB induction_NN over_IN the_DT 0_CD time_NN
          point_NN which_WDT was_VBD set_VBN empirically_RB as_IN 1_CD ._. This_DT data_NNS shown_VBN in_IN
          Figure_NN 3_CD Aindicates_NNP that_DT gene_NN expression_NN is_VBZ increased_VBN by_IN 8_CD
          hours_NNS and_CC reaches_VBZ maximum_NN induction_NN by_IN 24_CD hours_NNS ._. The_DT
          internal_JJ control_NN ,_, Renilla_NNP luciferase_NN ,_, increase_NN steadily_RB
          with_IN time_NN ,_, reflecting_VBG the_DT increase_NN in_IN cell_NN number_NN ,_, but_CC
          the_DT increase_NN was_VBD the_DT same_JJ with_IN DMSO_NNP or_CC GS-E_NNP treatment_NN
          (_( raw_JJ data_NNS not_RB shown_VBN but_CC effect_NN accounted_VBD for_IN in_IN the_DT
          calculation_NN as_IN defined_VBN above_IN )_) ._.
          The_DT sensitivity_NN of_IN the_DT gene_NN expression_NN system_NN to_TO
          varying_VBG doses_NNS of_IN GS-E_NNP was_VBD determined_VBN by_IN treating_VBG
          duplicate_VB samples_NNS of_IN clone_NN MBT-_NNP 2_CD +_NN RHeoSwitch-_NNP 2_CD +_NN luc-_NN 5_CD B_NNP 3_CD
          with_IN varying_VBG concentrations_NNS of_IN GS-E_NNP for_IN 24_CD or_CC 48_CD hours_NNS
          and_CC dual_JJ luciferase_NN assays_NNS were_VBD performed_VBN on_IN the_DT cell_NN
          lysates_NNS (_( Figure_NN 3_CD B_NNP )_) ._. Data_NNP were_VBD plotted_VBD as_IN a_DT
          GS-E_NNP (_( RLU_NNP 1_CD /_NN RLU_NNP 2_LS )_) /_NN Control_NNP (_( RLU_NNP 1_CD /_NN RLU_NNP 2_LS )_) ratio_NN (_( as_IN in_IN Table_NNP 1_LS )_)
          fold_VB induction_NN over_IN the_DT 0_CD drug_NN concentration_NN which_WDT was_VBD
          set_VBN empirically_RB as_IN 1_CD ._. These_DT results_NNS show_VBP an_DT increase_NN in_IN
          gene_NN inducing_VBG activity_NN with_IN increasing_VBG GS-E_NNP
          concentrations_NNS up_IN to_TO 10_CD μM_NN ._. A_DT significant_JJ increase_NN was_VBD
          seen_VBN with_IN as_RB little_JJ as_IN 1_CD μM_NN GS-E_NNP ._. No_DT change_NN was_VBD seen_VBN in_IN
          the_DT level_NN of_IN the_DT internal_JJ control_NN Renilla_NNP luciferase_NN with_IN
          varying_VBG concentrations_NNS of_IN GS-E_NNP (_( raw_JJ data_NNS not_RB shown_VBN but_CC
          effect_NN accounted_VBD for_IN in_IN the_DT calculation_NN as_IN defined_VBN
          above_IN )_) ._.
          The_DT decay_NN characteristics_NNS of_IN the_DT induction_NN were_VBD also_RB
          studied_VBN ._. After_IN a_DT 24_CD hour_NN incubation_NN ,_, the_DT medium_NN
          containing_VBG GS-E_NNP was_VBD removed_VBN and_CC the_DT cells_NNS washed_VBD three_CD
          times_NNS with_IN complete_JJ medium_NN without_IN GS-E_NNP ._. The_DT cells_NNS were_VBD
          then_RB re_NN incubated_JJ for_IN various_JJ durations_NNS ._. At_IN set_VBN intervals_NNS
          replicate_VB wells_NNS were_VBD removed_VBN and_CC dual_JJ luciferase_NN assays_NNS
          were_VBD performed_VBN on_IN the_DT cell_NN lysates_NNS (_( Figure_NN 4_CD A_DT )_) ._. This_DT data_NNS
          indicates_VBZ that_IN the_DT GS-E_NNP mediated_JJ induction_NN is_VBZ completely_RB
          reversible_JJ and_CC that_IN this_DT occurs_VBZ within_IN 48_CD hours_NNS ._.
          Similar_JJ dose_NN response_NN and_CC time_NN course_NN of_IN induction_NN of_IN
          gene_NN expression_NN experiments_NNS were_VBD performed_VBN on_IN the_DT Panc_NNP 02_CD
          cells_NNS containing_VBG the_DT RHeoSwitch_NNP and_CC the_DT inducible_JJ
          reporter_NN genes_NNS ._. The_DT time_NN course_NN of_IN gene_NN induction_NN
          demonstrated_VBN for_IN four_CD independent_JJ
          Panc_NNP 02_CD +_NN RHeoSwitch_NNP +_NN luciferase_NN cell_NN clones_NNS each_DT showed_VBD an_DT
          increase_NN within_IN 12_CD hours_NNS of_IN GS-E_NNP treatment_NN and_CC reached_VBD
          the_DT maximum_NN induction_NN by_IN 24_CD hours_NNS ._. Four_CD independent_JJ
          Panc_NNP 02_CD +_NN RHeoSwitch_NNP +_NN SEAP_NNP clones_NNS also_RB induced_VBN expression_NN by_IN
          12_CD hours_NNS but_CC the_DT level_NN of_IN SEAP_NNP activity_NN continued_VBD to_TO
          increase_VB for_IN 72_CD hours_NNS ,_, possibly_RB due_JJ to_TO the_DT accumulation_NN
          of_IN the_DT enzyme_NN in_IN the_DT cell_NN culture_NN media_NNS over_IN the_DT entire_JJ
          treatment_NN time_NN ._. Treatment_NNP of_IN five_CD of_IN these_DT independent_JJ
          Panc_NNP 02_CD +_NN RHeoSwitch_NNP +_NN reporter_NN gene_NN clones_NNS with_IN varying_VBG doses_NNS
          of_IN GS-E_NNP consistently_RB yielded_VBD a_DT significant_JJ induction_NN in_IN
          gene_NN expression_NN with_IN 1_CD μM_NN GS-E_NNP (_( 23_CD ._. 5_LS -_: fold_VB induction_NN over_IN
          DMSO_NNP treatment_NN alone_RB )_) and_CC a_DT maximal_NN induction_NN with_IN 15_CD μM_NN
          GS-E_NNP (_( 80_CD ._. 2_LS -_: fold_VB induction_NN over_IN DMSO_NNP )_) ._. The_DT dose_NN response_NN
          and_CC time_NN course_NN of_IN induction_NN in_IN the_DT Panc_NNP 02_CD cells_NNS were_VBD
          similar_JJ to_TO the_DT results_NNS seen_VBN in_IN experiments_NNS on_IN the_DT MBT-_NNP 2_CD
          cells_NNS ._. These_DT results_NNS show_VBP that_IN the_DT RHeoSwitch_NNP gene_NN
          induction_NN system_NN gives_VBZ consistent_JJ results_NNS independent_JJ of_IN
          the_DT cell_NN type_NN being_VBG used_VBN ,_, the_DT reporter_NN gene_NN used_VBN to_TO
          assess_VB the_DT activity_NN ,_, as_RB well_RB as_IN the_DT chromosomal_NN
          integration_NN site_NN of_IN the_DT DNA_NNP encoding_VBG the_DT RHeoSwitch_NNP
          components_NNS (_( compare_VB Panc_NNP 02_CD +_NN RHeoSwitch-_NNP 3_CD and_CC -_: 4_CD described_VBD
          above_IN )_) or_CC the_DT integration_NN site_NN of_IN the_DT reporter_NN gene_NN DNA_NNP
          (_( compare_VB multiple_JJ reporter_NN clones_NNS from_IN each_DT of_IN three_CD
          RHeoSwitch_NNP clones_NNS described_VBD above_IN )_) ._.
        
        
          In_IN vivo_NN results_NNS
          The_DT potency_NN and_CC favorable_JJ kinetics_NNS of_IN GS-E_NNP as_IN an_DT
          ecdysone-system_JJ inducer_NN in_IN vitro_NN in_IN both_DT the_DT pancreatic_JJ
          and_CC bladder_NN cell_NN lines_NNS led_VBD us_PRP to_TO evaluate_VB its_PRP$ performance_NN
          in_IN vivo_NN in_IN a_DT bladder_NN xenograft_NN model_NN ._. To_TO measure_VB the_DT
          pharmacokinetics_NNS of_IN GSE_NNP mediated_JJ gene_NN induction_NN in_IN
          animals_NNS ,_, we_PRP inoculated_JJ the_DT MBT-_NNP 2_CD murine_NN bladder_NN cancer_NN
          cell_NN line_NN into_IN syngeneic_JJ mice_NNS and_CC after_IN the_DT tumors_NNS
          reached_VBD 0_CD ._. 4_CD -_: 0_CD ._. 5_LS mm_NN in_IN diameter_NN ,_, the_DT mice_NNS were_VBD treated_VBN
          with_IN GS-E_NNP ._. At_IN 6_CD ,_, 12_CD and_CC 24_CD hour_NN intervals_NNS following_VBG
          inoculation_NN ,_, the_DT tumors_NNS were_VBD excised_VBN and_CC analyzed_VBD for_IN
          luciferase_NN induction_NN ._. Luciferase_NNP protein_NN was_VBD chosen_VBN
          primarily_RB because_IN its_PRP$ 3_CD -_: 4_CD hour_NN half-life_NN in_IN mammalian_JJ
          cell_NN allows_VBZ precise_JJ kinetic_JJ studies_NNS [_NN 15_CD ]_NN ._. The_DT renilla_NN
          luciferase_NN was_VBD used_VBN as_IN an_DT internal_JJ control_NN in_IN addition_NN to_TO
          untreated_JJ mice_NNS ._. Data_NNP shown_VBN in_IN Figure_NN 4_CD Bindicates_NNP that_DT
          induction_NN of_IN luciferase_NN activity_NN in_IN tumor_NN xenografts_NNS is_VBZ
          prompt_JJ ,_, peaking_VBG between_IN 6_CD -_: 12_CD hours_NNS ._. In_IN addition_NN ,_, decay_NN of_IN
          the_DT effect_NN occurs_VBZ swiftly_RB and_CC baseline_NN expression_NN levels_NNS
          are_VBP reached_VBN by_IN 12_CD -_: 24_CD hours_NNS ._. Although_IN available_JJ to_TO us_PRP ,_, the_DT
          identification_NN of_IN cell_NN specific_JJ expression_NN within_IN the_DT
          tumor_NN using_VBG the_DT induction_NN of_IN GFP_NNP in_IN these_DT tumor_NN cells_NNS was_VBD
          complicated_VBN by_IN the_DT decrease_NN in_IN the_DT level_NN of_IN GFP_NNP
          expression_NN (_( data_NNS not_RB shown_VBN )_) ,_, presumably_RB due_JJ to_TO position_VB
          effect_NN variegation_NN of_IN the_DT transfected_JJ DNA_NNP as_RB well_RB as_IN poor_JJ
          quantitation_NN ability_NN ._.
        
      
      
        Discussion_NNP
        Methods_NNP devised_VBD to_TO control_VB gene_NN expression_NN must_MD allow_VB
        for_IN rapid_JJ ,_, robust_JJ ,_, precise_JJ ,_, and_CC reversible_JJ induction_NN of_IN
        gene_NN activity_NN ._. Because_IN steroids_NNS are_VBP small_JJ lipophilic_JJ
        molecules_NNS that_WDT penetrate_VB all_DT tissues_NNS and_CC are_VBP quickly_RB
        metabolized_VBN and_CC cleared_VBN ,_, they_PRP appear_VBP to_TO be_VB ideal_JJ inducers_NNS
        for_IN developing_VBG gene_NN regulation_NN systems_NNS that_WDT fulfill_VBP these_DT
        criteria_NNS ._. To_TO exploit_VB the_DT pharmacokinetics_NNS of_IN steroids_NNS while_IN
        eluding_VBG the_DT potential_JJ complications_NNS of_IN the_DT use_NN of_IN a_DT
        mammalian_JJ hormone_NN as_IN the_DT inducer_NN ,_, the_DT Evans_NNP laboratory_NN
        developed_VBD an_DT inducible_JJ system_NN based_VBN on_IN the_DT insect_NN steroid_NN
        ecdysone_NN and_CC the_DT nuclear_JJ receptor_NN that_IN mediates_NNS its_PRP$
        effects_NNS ._. [_NN 7_CD ]_NN This_DT system_NN is_VBZ comprised_VBN of_IN a_DT chimeric_JJ
        protein_NN composed_VBN of_IN the_DT VP_NNP 16_CD activation_NN domain_NN (_( Vg_NNP )_) fused_JJ
        to_TO an_DT ecdysone_NN receptor_NN (_( EcR_NNP )_) with_IN altered_VBN DNA-binding_NNP
        specificity_NN heterodimerizes_NNS with_IN the_DT retinoid_NN X_NNP receptor_NN
        (_( RXR_NNP )_) and_CC binds_NNS a_DT unique_JJ synthetic_JJ response_NN element_NN not_RB
        recognized_VBN by_IN natural_JJ nuclear_JJ hormone_NN receptors_NNS ._. Upon_IN
        exposure_NN to_TO the_DT ecdysone_NN analog_NN muristerone_NN A_DT (_( murA_NN )_) ,_, the_DT
        VgEcR_NNP /_NN RXR_NNP complex_JJ efficiently_RB induces_VBZ the_DT expression_NN of_IN
        reporter_NN genes_NNS in_IN mammalian_JJ cells_NNS and_CC transgenic_JJ animals_NNS ._.
        In_IN the_DT RHeoSwitch_NNP gene_NN expression_NN system_NN ,_, the_DT properties_NNS of_IN
        the_DT chimeric_JJ receptors_NNS have_VBP been_VBN optimized_JJ through_IN the_DT
        analysis_NN of_IN a_DT series_NN of_IN truncation_NN and_CC site-directed_JJ
        mutations_NNS (_( Palli_NNP ,_, et_CC ._. al_NN ._. ,_, manuscript_NN in_IN preparation_NN )_) ._. This_DT
        study_NN demonstrates_VBZ the_DT utility_NN of_IN a_DT first_JJ generation_NN system_NN
        in_IN vitro_NN and_CC in_IN vivo_NN and_CC subsequent_JJ modified_VBN versions_NNS of_IN
        the_DT RHeoSwitch_NNP will_MD be_VB sensitive_JJ to_TO lower_JJR concentrations_NNS of_IN
        ligand_NN and_CC result_NN in_IN higher_JJR levels_NNS of_IN induced_VBN gene_NN
        expression_NN (_( see_VB www_NN ._. RHeoGene_NNP ._. com_NN )_) ._.
        The_DT popularity_NN of_IN the_DT ecdysone-inducible_JJ gene_NN switch_NN led_VBN
        to_TO the_DT unexpected_JJ rapid_JJ depletion_NN of_IN murA_NN stocks_NNS ,_, the_DT
        primary_JJ inducer_NN used_VBN in_IN the_DT system_NN ._. MurA_NNP was_VBD isolated_VBN in_IN
        the_DT early_JJ 1970_CD s_VBZ from_IN the_DT seeds_NNS of_IN kaladana_NN (_( Ipomoea_NNP
        calonyction_NN )_) ,_, a_DT plant_NN native_JJ to_TO the_DT southern_JJ slopes_NNS of_IN the_DT
        Himalayas_NNP ._. [_NN 10_CD ]_NN The_DT difficulty_NN in_IN obtaining_VBG kaladana_NN
        seeds_NNS prompted_VBD efforts_NNS to_TO seek_VB alternative_JJ inducers_NNS derived_VBN
        from_IN more_RBR common_JJ plants_NNS or_CC synthetic_JJ analogs_NNS such_JJ as_IN GS-E_NNP ._.
        GS-E_NNP is_VBZ one_CD of_IN a_DT family_NN of_IN diacylhydrazines_NNS that_WDT have_VBP been_VBN
        found_VBN to_TO act_VB as_IN non-steroidal_JJ ecdysone_NN mimics_VBZ that_WDT can_MD
        function_VB as_IN gene_NN inducers_NNS [_NN 16_CD ]_NN ._.
        The_DT avalanche_NN of_IN new_JJ genes_NNS resulting_VBG from_IN completion_NN of_IN
        the_DT genome_NN project_NN has_VBZ accentuated_JJ the_DT need_NN to_TO develop_VB
        methods_NNS to_TO determine_VB gene_NN function_NN ._. The_DT requirement_NN for_IN
        tight_JJ regulation_NN ,_, easy_JJ titration_NN and_CC minimal_JJ background_NN
        expression_NN is_VBZ particularly_RB important_JJ in_IN the_DT study_NN of_IN genes_NNS
        such_JJ as_IN tumor_NN suppressors_NNS or_CC cell_NN cycle_NN regulatory_JJ genes_NNS
        for_IN which_WDT cell_NN lines_NNS stably_RB expressing_VBG the_DT product_NN can_MD
        rarely_RB be_VB made_VBN ._. In_IN addition_NN ,_, deliberate_JJ manipulation_NN of_IN
        gene_NN activity_NN is_VBZ also_RB an_DT indispensable_JJ tool_NN for_IN clinical_JJ
        applications_NNS such_JJ as_IN gene_NN therapy_NN ._. The_DT strengths_NNS of_IN the_DT
        ecdysone-inducible_JJ system_NN appear_VBP to_TO be_VB its_PRP$ tight_JJ
        regulation_NN ,_, its_PRP$ dose_NN responsiveness_NNS ,_, and_CC the_DT favorable_JJ
        uptake_NN and_CC clearance_NN kinetics_NNS of_IN the_DT inducer_NN ,_, which_WDT results_VBZ
        in_IN rapid_JJ gene_NN switching_NN ._. Thus_RB it_PRP appears_VBZ ideal_JJ for_IN both_DT the_DT
        in_IN vitro_NN and_CC in_IN vivo_NN study_NN of_IN newly_RB characterized_VBN genes_NNS in_IN
        their_PRP$ role_NN in_IN tumor_NN formation_NN and_CC progression_NN ._. In_IN vitro_NN
        data_NNS indicates_VBZ that_IN our_PRP$ constructs_NNS when_WRB used_VBN in_IN combination_NN
        with_IN GS-E_NNP ,_, offer_NN an_DT excellent_JJ induction_NN profile_NN and_CC rapid_JJ
        decay_NN of_IN gene_NN expression_NN when_WRB the_DT compound_NN is_VBZ removed_VBN from_IN
        in_IN vitro_NN culture_NN ._. Importantly_NNP ,_, we_PRP have_VBP demonstrated_VBN similar_JJ
        kinetics_NNS for_IN 2_CD different_JJ cancer_NN cell_NN lines_NNS with_IN 2_CD different_JJ
        reporters_NNS (_( F-_NNP luc_NN and_CC SEAP_NNP )_) thus_RB validating_VBG the_DT generality_NN
        of_IN the_DT observed_VBN results_NNS ._. In_IN addition_NN ,_, these_DT constructs_NNS are_VBP
        also_RB associated_VBN with_IN a_DT low_JJ baseline_NN gene_NN expression_NN level_NN
        allowing_VBG the_DT study_NN of_IN genes_NNS whose_WP$ expression_NN may_MD be_VB
        incompatible_JJ with_IN the_DT generation_NN of_IN constitutively_RB
        expressing_VBG clones_NNS ._. A_DT recent_JJ report_NN showed_VBD that_IN the_DT
        expression_NN of_IN nonmuscle_NN myosin_NN heavy_JJ chain-_NN B_NNP induced_VBN by_IN
        Muristerone_NNP A_DT in_IN vitro_NN [_NN 8_CD ]_NN suppressed_VBD the_DT subsequent_JJ
        tumorigenicity_NN of_IN the_DT implanted_VBN cells_NNS in_IN vivo_NN ._.
        The_DT potency_NN and_CC favorable_JJ kinetics_NNS of_IN the_DT cell_NN lines_NNS we_PRP
        developed_VBD in_IN conjunction_NN with_IN GS-E_NNP as_IN an_DT ecdysone-system_JJ
        inducer_NN in_IN vitro_NN in_IN both_DT the_DT pancreatic_JJ and_CC bladder_NN cell_NN
        lines_NNS led_VBD us_PRP to_TO evaluate_VB the_DT performance_NN of_IN this_DT system_NN in_IN
        vivo_NN in_IN a_DT bladder_NN cancer_NN xenograft_NN model_NN ._. The_DT advantages_NNS of_IN
        the_DT MBT-_NNP 2_CD murine_NN bladder_NN tumor_NN model_NN are_VBP several_JJ fold_VB ._.
        First_LS ,_, it_PRP was_VBD derived_VBN by_IN chemical_NN carcinogenesis_NNS ,_, the_DT most_RBS
        common_JJ known_VBN etiologic_JJ factor_NN in_IN bladder_NN cancer_NN ._. Second_JJ ,_,
        when_WRB inoculated_JJ orthotopically_RB it_PRP reproduces_NNS the_DT biology_NN of_IN
        human_JJ muscle_NN invasive_JJ bladder_NN cancer_NN ._. Thirdly_NNP ,_, it_PRP has_VBZ been_VBN
        widely_RB used_VBN as_IN a_DT model_NN system_NN of_IN various_JJ therapeutic_JJ
        interventions_NNS in_IN bladder_NN cancer_NN ._. [_NN 12_CD 13_CD ]_NN Interestingly_RB ,_,
        our_PRP$ data_NNS indicates_VBZ that_IN the_DT kinetics_NNS of_IN induction_NN of_IN tumor_NN
        luciferase_NN in_IN response_NN to_TO GS-E_NNP mirror_VBP those_DT observed_VBN with_IN
        transgenic_JJ mice_NNS in_IN response_NN to_TO PonA_NNP ._. [_NN 10_CD ]_NN This_DT finding_VBG
        may_MD indicate_VB that_IN despite_IN their_PRP$ use_NN in_IN a_DT malignant_JJ context_NN ,_,
        the_DT ecdysone_NN constructs_NNS behave_VB with_IN similar_JJ kinetics_NNS to_TO
        that_DT in_IN normal_JJ cells_NNS thus_RB implying_VBG a_DT general_JJ utility_NN in_IN
        studies_NNS of_IN various_JJ histological_JJ tumor_NN types_NNS ._. In_IN addition_NN ,_,
        comparison_NN of_IN the_DT in_IN vivo_NN (_( Figure_NN 4_CD B_NNP )_) and_CC in_IN vitro_NN (_( Figure_NN
        3_CD A_DT )_) induction_NN curves_NNS reveals_VBZ roughly_RB similar_JJ time_NN to_TO peak_VB
        induction_NN despite_IN the_DT fact_NN that_IN the_DT in_IN vivo_NN experiments_NNS
        were_VBD carried_VBN out_IN with_IN a_DT mixture_NN of_IN GS-E_NNP in_IN sesame_NN seed_NN oil_NN ,_,
        which_WDT purportedly_RB slows_VBZ its_PRP$ delivery_NN ._. [_NN 9_CD ]_NN
        Although_IN available_JJ to_TO us_PRP ,_, the_DT identification_NN of_IN cell_NN
        specific_JJ expression_NN within_IN the_DT tumor_NN using_VBG the_DT induction_NN of_IN
        GFP_NNP in_IN these_DT tumor_NN cells_NNS was_VBD complicated_VBN by_IN the_DT decrease_NN in_IN
        the_DT level_NN of_IN GFP_NNP expression_NN ,_, presumably_RB due_JJ to_TO position_VB
        effect_NN variegation_NN of_IN the_DT transfected_JJ DNA_NNP ._. In_IN addition_NN ,_, the_DT
        utility_NN of_IN GFP_NNP for_IN the_DT localization_NN of_IN gene_NN expression_NN in_IN
        vivo_NN ,_, particularly_RB in_IN conditions_NNS of_IN hypoxia_NN ,_, such_JJ as_IN
        tumors_NNS ,_, has_VBZ been_VBN recently_RB been_VBN questioned_VBN [_NN 17_CD ]_NN ._. Finally_RB ,_,
        quantitative_JJ analysis_NN of_IN tumor_NN GFP_NNP induction_NN is_VBZ difficult_JJ
        and_CC less_RBR reliable_JJ than_IN other_JJ reporters_NNS such_JJ as_IN luciferase_NN ._.
        Therefore_RB we_PRP have_VBP limited_JJ our_PRP$ in_IN vivo_NN experiments_NNS
        determining_VBG the_DT general_JJ level_NN of_IN gene_NN induction_NN within_IN the_DT
        tumor_NN by_IN using_VBG a_DT luciferase_NN reporter_NN which_WDT has_VBZ been_VBN proven_VBN
        to_TO be_VB reliable_JJ in_IN vivo_NN ._.
      
      
        Conclusions_NNP
        We_PRP have_VBP used_VBN a_DT modified_VBN ecdysone_NN reporter_NN system_NN which_WDT
        has_VBZ favorable_JJ baseline_NN and_CC induction_NN kinetics_NNS in_IN response_NN
        to_TO a_DT novel_NN ecdysone_NN analog_NN GS-E_NNP in_IN murine_NN tumors_NNS in_IN vitro_NN ._.
        We_PRP have_VBP demonstrated_VBN the_DT general_JJ applicability_NN of_IN this_DT
        system_NN by_IN demonstrating_VBG its_PRP$ use_NN in_IN two_CD different_JJ mouse_NN
        tumor_NN cell_NN lines_NNS ,_, integration_NN of_IN the_DT RHeoSwitch_NNP DNA_NNP
        components_NNS at_IN multiple_JJ chromosomal_NN locations_NNS ,_, as_RB well_RB as_IN
        with_IN 2_CD different_JJ gene_NN reporters_NNS ,_, luciferase_NN ,_, and_CC SEAP_NNP ._. We_PRP
        have_VBP presented_VBN data_NNS that_WDT is_VBZ the_DT first_JJ demonstration_NN of_IN
        tumor_NN cell_NN lines_NNS stably_RB transfected_JJ with_IN an_DT ecdysone_NN
        inducible_JJ constructs_NNS tested_VBN in_IN vivo_NN demonstrating_VBG that_IN in_IN
        vivo_NN these_DT constructs_NNS coupled_VBN with_IN GS-E_NNP allow_VB rapid_JJ and_CC
        robust_JJ induction_NN of_IN gene_NN expression_NN in_IN tumor_NN xenografts_NNS ._.
        Finally_RB ,_, due_JJ to_TO the_DT rapid_JJ decay_NN of_IN gene_NN expression_NN
        following_VBG maximal_NN activation_NN ,_, this_DT system_NN can_MD be_VB easily_RB
        titrated_JJ for_IN the_DT duration_NN of_IN the_DT induction_NN necessary_JJ by_IN
        using_VBG slow_JJ release_NN formulations_NNS such_JJ as_IN ALZET_NNP mini_NN pumps_NNS [_NN
        18_CD ]_NN ._. The_DT postgenomic_JJ era_NN has_VBZ accentuated_JJ the_DT need_NN to_TO
        develop_VB methods_NNS to_TO determine_VB in_IN vivo_NN gene_NN function_NN in_IN
        cancer_NN and_CC this_DT ecdysone_NN system_NN may_MD be_VB a_DT useful_JJ approach_NN to_TO
        address_VB this_DT ._.
      
      
        materials_NNS and_CC methods_NNS
        
          Cell_NNP culture_NN and_CC plasmid_NN DNA_NNP constructs_NNS
          MBT-_NNP 2_CD murine_NN urothelial_NN cancer_NN cells_NNS and_CC their_PRP$ culture_NN
          conditions_NNS for_IN passage_NN were_VBD previously_RB described_VBN ._. [_NN 12_CD ]_NN
          The_DT murine_NN ductal_NN cell_NN pancreatic_JJ adenocarcinoma_NN cell_NN
          line_NN ,_, Panc_NNP 02_CD [_NN 19_CD ]_NN ,_, was_VBD kindly_RB provided_VBN by_IN Dr_NNP ._. James_NNP
          Nelson_NNP ,_, MD_NNP Anderson_NNP Cancer_NNP Center_NNP ._. Plasmid_NNP DNA_NNP was_VBD
          prepared_VBN by_IN the_DT "_'' EndoFree_NNP Plasmid_NNP Maxi_NNP kit_NN "_'' from_IN Qiagen_NNP
          (_( Valencia_NNP ,_, CA_NNP )_) using_VBG the_DT manufacturer_NN 's_POS procedure_NN ._. Cells_NNP
          were_VBD simultaneously_RB co-transfected_JJ by_IN electroporation_NN
          (_( Gene_NNP Pulser_NNP ,_, Bio-_NNP Rad_NNP Inc_NNP ._. )_) with_IN pGAL_NN 4_CD -_: EcR_NNP ,_, pVP_NN 16_CD -_: mRXR_NN ,_,
          pRL-TK_JJ (_( Renilla_NNP luciferase_NN )_) and_CC pGAL_NN 4_CD -_: EGFP_NNP ._. The_DT plasmids_NNS
          pGAL_NN 4_CD -_: EcR_NNP encodes_NNS a_DT fusion_NN protein_NN between_IN the_DT yeast_NN GAL_NNP 4_CD
          DNA_NNP binding_JJ domain_NN and_CC the_DT ligand_NN binding_JJ domain_NN of_IN the_DT
          ecdysone_NN receptor_NN from_IN the_DT spruce_VB budworm_NN ,_, Choristoneura_NNP
          occidentalis_NNS ._. Plasmid_NNP pVP_NN 16_CD -_: mRXR_NN encodes_NNS a_DT fusion_NN protein_NN
          between_IN the_DT transcriptional_NN transactivator_NN VP_NNP 16_CD from_IN
          Herpes_NNP simplex_NN virus_NN (_( HSV_NNP )_) and_CC the_DT mouse_NN RXR_NNP protein_NN ._. The_DT
          vector_NN pRL-TK_JJ (_( Promega_NNP )_) ,_, expressing_VBG the_DT Renilla_NNP
          luciferase_NN enzyme_NN from_IN the_DT HSV_NNP thymidine_NN kinase_NN (_( TK_NNP )_)
          promoter_NN ,_, was_VBD included_VBN as_IN an_DT uninduced_JJ constitutively_RB
          expressed_VBD internal_JJ control_NN ._. The_DT vector_NN pGAL_NN 4_CD -_: EGFP_NNP was_VBD
          constructed_VBN from_IN pCI-neo_JJ (_( Promega_NNP )_) by_IN replacing_VBG the_DT CMV_NNP
          promoter_NN and_CC enhancer_NN with_IN a_DT fragment_NN from_IN pG_NN 5_CD -_: luc_NN
          (_( Promega_NNP )_) containing_VBG the_DT 5_CD ×_NN GAL_NNP 4_CD recognition_NN sequences_NNS
          and_CC the_DT minimal_JJ promoter_NN from_IN the_DT adenoviral_NN late_JJ
          promoter_NN and_CC the_DT EGFP_NNP gene_NN from_IN pEGFP_NN (_( Clontech_NNP )_) ._. In_IN
          addition_NN to_TO the_DT GAL_NNP 4_CD -_: EGFP_NNP expression_NN cassette_NN ,_, this_DT
          plasmid_NN contains_VBZ the_DT neomycin_NN resistance_NN gene_NN under_IN the_DT
          control_NN of_IN the_DT SV_NNP 40_CD promoter_NN and_CC enhancer_NN for_IN selection_NN
          of_IN transfected_JJ cells_NNS in_IN G_NNP 418_CD ._.
        
        
          Transfection_NNP and_CC isolation_NN of_IN clones_NNS stably_RB
          transfected_JJ with_IN inducible_JJ reporter_NN gene_NN plasmids_NNS
          Cells_NNP were_VBD transfected_JJ by_IN electroporation_NN with_IN
          mixtures_NNS of_IN the_DT four_CD plasmids_NNS which_WDT had_VBD been_VBN linearized_JJ
          by_IN restriction_NN enzyme_NN digestion_NN ._. Following_VBG transfection_NN ,_,
          cells_NNS were_VBD allowed_VBN to_TO recover_VB for_IN 24_CD h_NN prior_RB and_CC were_VBD
          then_RB selected_VBN in_IN 500_CD μg_NN /_NN ml_NN G_NNP 418_CD for_IN MBT-_NNP 2_CD cells_NNS and_CC 700_CD
          μg_NN /_NN ml_NN G_NNP 418_CD for_IN Panc_NNP 02_CD cells_NNS for_IN three_CD weeks_NNS ._. Cells_NNP were_VBD
          then_RB cloned_VBN by_IN limited_JJ dilution_NN into_IN 96_CD well_RB plates_NNS ._.
          Expression_NNP of_IN green_JJ fluorescent_NN protein_NN (_( GFP_NNP )_) was_VBD induced_VBN
          by_IN addition_NN of_IN GS-E_NNP
          (_( A_DT /_NN -_: (_( 3_CD -_: methoxy-_NN 2_CD -_: ethylbenzoyl_NN )_) -_: A_DT /_NN '_'' -_: (_( 3_CD ,_, 5_CD -_: dimethylbenzoyl_NN )_) -_: A_DT /_NN '_'' -_: tert-butylhydrazine_JJ )_) ._.
          GS-E_NNP is_VBZ a_DT member_NN of_IN the_DT bisacylhydrazine_NN chemical_NN family_NN
          which_WDT has_VBZ been_VBN shown_VBN to_TO have_VB no_DT adverse_JJ effects_NNS over_IN a_DT
          broad_JJ dosage_NN range_NN in_IN mammals_NNS ._. [_NN 11_CD ]_NN The_DT 96_CD well_RB plates_NNS
          were_VBD visualized_JJ under_IN a_DT fluorescent_NN microscope_NN before_IN and_CC
          after_IN addition_NN of_IN the_DT compound_NN ._. Clones_NNP exhibiting_VBG low_JJ
          background_NN of_IN green_JJ fluorescence_NN prior_RB to_TO addition_NN of_IN the_DT
          compound_NN and_CC high_JJ levels_NNS following_VBG the_DT addition_NN were_VBD
          selected_VBN for_IN further_JJ transfections_NNS ._.
          Cell_NNP clones_NNS were_VBD transiently_RB transfected_JJ using_VBG
          Superfect_NNP reagent_NN with_IN 1_CD μg_NN per_IN well_RB of_IN 6_CD well_RB plate_NN with_IN
          either_DT pFR-luc_JJ (_( Promega_NNP )_) or_CC pGAL_NN 4_CD -_: SEAP_NNP (_( secreted_JJ alkaline_NN
          phosphatase_NN )_) (_( provided_VBN by_IN Dr_NNP ._. R_NN ._. Herzig_NNP ,_, Rheogene_NNP Inc_NNP ._. )_)
          and_CC 3_CD μg_NN carrier_NN DNA_NNP (_( pLITMUS_NN ,_, New_NNP England_NNP Biolabs_NNP )_) ._. To_TO
          three_CD wells_NNS ,_, DMSO_NNP was_VBD added_VBN to_TO a_DT final_JJ concentration_NN of_IN
          0_CD ._. 3_CD %_NN v_NN /_NN v_NN ._. GS-E_NNP in_IN DMSO_NNP was_VBD added_VBN to_TO the_DT remaining_VBG three_CD
          wells_NNS to_TO a_DT final_JJ GS-E_NNP concentration_NN of_IN 15_CD μM_NN and_CC DMSO_NNP
          concentration_NN of_IN 0_CD ._. 3_CD %_NN ._. Cells_NNP were_VBD treated_VBN for_IN 24_CD hours_NNS ,_,
          at_IN which_WDT time_NN they_PRP were_VBD collected_VBN in_IN Passive_NNP Lysis_NNP Buffer_NNP
          and_CC the_DT activity_NN of_IN firefly_RB and_CC Renilla_NNP luciferase_NN in_IN the_DT
          cell_NN extract_NN was_VBD determined_VBN ._. The_DT clone_NN exhibiting_VBG the_DT
          highest_JJS level_NN of_IN induced_VBN gene_NN expression_NN was_VBD then_RB used_VBN
          for_IN further_JJ development_NN ._. These_DT cells_NNS where_WRB in_IN turn_NN
          co-transfected_JJ with_IN pSV_NN 40_CD /_NN Zeo_NNP 2_CD (_( Invitrogen_NNP )_) and_CC pG_NN 5_CD -_: luc_NN
          (_( Promega_NNP )_) ,_, encoding_VBG firefly_RB luciferase_NN or_CC pGAL_NN 4_CD -_: SEAP_NNP and_CC
          MBT-_NNP 2_CD cells_NNS were_VBD selected_VBN in_IN 400_CD μg_NN /_NN ml_NN Zeocin_NNP and_CC Panc_NNP 02_CD
          cells_NNS in_IN 500_CD μg_NN /_NN ml_NN Zeocin_NNP ._. Zeocin_NNP resistant_JJ cells_NNS were_VBD
          then_RB cloned_VBN by_IN limiting_VBG dilution_NN into_IN 96_CD well_RB plates_NNS ._.
          Replica_NNP plates_NNS were_VBD then_RB created_VBN and_CC induction_NN of_IN
          luciferase_NN activity_NN in_IN response_NN to_TO GS-E_NNP carried_VBD out_IN as_IN
          for_IN GFP_NNP ._. Clones_NNP exhibiting_VBG low_JJ background_NN luciferase_NN
          expression_NN prior_RB to_TO addition_NN of_IN the_DT compound_NN and_CC high_JJ
          levels_NNS following_VBG the_DT addition_NN were_VBD selected_VBN for_IN further_RB
          in_IN vivo_NN and_CC in_IN vitro_NN study_NN ._.
        
        
          Measurement_NNP of_IN reporter_NN protein_NN levels_NNS in_IN vitro_NN and_CC
          in_IN vivo_NN
          To_TO determine_VB the_DT luciferase_NN activity_NN ,_, cells_NNS or_CC tissues_NNS
          were_VBD lysed_JJ in_IN Passive_NNP Lysis_NNP Buffer_NNP (_( Promega_NNP )_) and_CC assayed_JJ
          for_IN firefly_RB (_( F-_NNP luc_NN )_) and_CC Renilla_NNP (_( R-L_NNP uc_NN )_) luciferase_NN
          according_VBG to_TO the_DT Promega_NNP Luciferase_NNP assay_NN kit_NN
          instructions_NNS in_IN a_DT Turner_NNP Designs_NNS (_( Sunnyvale_NNP ,_, CA_NNP )_) TD-_NNP 20_CD /_NN 20_CD
          or_CC a_DT PharMingen_NNP Monolight_NNP 3010_CD luminometer_NN ._. The_DT
          luciferase_NN activity_NN was_VBD recorded_VBN as_IN Relative_NNP Light_NNP Units_NNS
          (_( RLU_NNP )_) ._.
          For_IN the_DT determination_NN of_IN SEAP_NNP levels_NNS ,_, cells_NNS were_VBD
          treated_VBN with_IN DMSO_NNP or_CC GS-E_NNP for_IN 48_CD hours_NNS ._. Media_NNP was_VBD removed_VBN
          from_IN all_DT cultures_NNS and_CC either_CC assayed_JJ or_CC stored_VBD at_IN -_: 20_CD
          degrees_NNS until_IN assayed_JJ ._. Assays_NNP were_VBD performed_VBN using_VBG the_DT
          chemiluminescent_NN SEAP_NNP assay_NN procedure_NN as_IN described_VBN by_IN the_DT
          manufacturer_NN in_IN the_DT Great_NNP EscAPe_NNP SEAP_NNP Assay_NNP system_NN
          (_( Clontech_NNP )_) ._. The_DT chemiluminescent_NN signal_NN was_VBD measured_VBN with_IN
          a_DT PharMingen_NNP Monolight_NNP 3010_CD luminometer_NN and_CC recorded_VBN as_IN
          Relative_NNP Light_NNP Units_NNS (_( RLU_NNP )_) ._.
        
        
          In_IN vivo_NN tumor_NN assays_NNS
          Six-to-_NNP 8_CD week-old_JJ C_NNP 3_CD H_NNP /_NN He_PRP origin_NN mice_NNS were_VBD obtained_VBN
          from_IN Taconic_NNP Farms_NNP (_( www_NN ._. taconic_JJ ._. com_NN )_) and_CC maintained_VBN
          strictly_RB according_VBG to_TO approved_VBD Institutional_NNP Animal_NNP Care_NNP
          and_CC Use_NNP Committee_NNP protocols_NNS ._. Food_NNP and_CC water_NN were_VBD provided_VBN
          ad_NN libitum_NN ._. Cohorts_NNP of_IN mice_NNS were_VBD given_VBN injections_NNS in_IN the_DT
          anterior_NN flank_NN (_( 2_CD sites_NNS per_IN mouse_NN )_) with_IN 10_CD 6_CD tumor_NN cells_NNS
          suspended_VBN in_IN 0_CD ._. 1_CD ml_NN of_IN serum_NN free_JJ medium_NN ._. Mice_NNS were_VBD
          examined_VBN every_DT week_NN ,_, and_CC tumors_NNS were_VBD measured_VBN with_IN
          calipers_NNS in_IN the_DT greatest_JJS 2_CD diameters_NNS ._. When_WRB tumors_NNS reached_VBD
          5_CD mm_NN in_IN greatest_JJS diameter_NN ,_, mice_NNS were_VBD injected_VBN
          intraperitoneally_RB with_IN either_DT 45_CD milligrams_NNS of_IN GS-E_NNP
          dissolved_VBN in_IN 90_CD μl_NN of_IN DMSO_NNP and_CC 360_CD μl_NN of_IN sesame_NN oil_NN or_CC
          with_IN equivalent_NN volumes_NNS of_IN DMSO_NNP and_CC 360_CD μl_NN of_IN sesame_NN oil_NN
          alone_RB ._. Cohorts_NNP of_IN 3_CD mice_NNS were_VBD euthanized_JJ 6_CD ,_, 12_CD and_CC 24_CD
          hours_NNS following_VBG drug_NN administration_NN and_CC cohorts_NNS of_IN 2_CD mice_NNS
          euthanized_JJ 6_CD and_CC 24_CD hours_NNS following_VBG vehicle_NN
          administration_NN and_CC tumors_NNS processed_VBN for_IN luciferase_NN
          activity_NN as_IN described_VBN above_IN ._. To_TO evaluate_VB the_DT reporter_NN
          induction_NN ,_, the_DT ratio_NN of_IN RLU_NNP from_IN firefly_RB (_( F-_NNP luc_NN )_) and_CC
          Renilla_NNP (_( R-L_NNP uc_NN )_) luciferase_NN was_VBD evaluated_VBN
          (_( RLU_NNP {_( F-_NNP luc_NN }_) /_NN RLU_NNP {_( R-_NNP luc_NN }_) )_) ._. This_DT time_NN course_NN was_VBD based_VBN on_IN
          the_DT pharmacokinetics_NNS of_IN PonA_NNP following_VBG this_DT route_NN of_IN
          administration_NN ._. [_NN 10_CD ]_NN
        
        
          Statistical_NNP analysis_NN
          All_DT in_IN vitro_NN assays_NNS were_VBD performed_VBN using_VBG duplicate_VB or_CC
          triplicate_NN samples_NNS and_CC error_NN bars_NNS represent_VBP one_CD standard_JJ
          error_NN from_IN the_DT mean_NN ._. Figures_NNS consist_VBP of_IN a_DT representative_NN
          experiment_NN carried_VBD out_RB at_IN least_JJS 2_CD -_: 3_CD times_NNS with_IN similar_JJ
          results_NNS ._. Data_NNP were_VBD plotted_VBD and_CC statistical_JJ analysis_NN was_VBD
          accomplished_VBN using_VBG the_DT STATISTICA_NNP for_IN Windows_NNP computer_NN
          program_NN (_( StatSoft_NNP ,_, Inc_NNP ._. Tulsa_NNP ,_, OK_JJ )_) ._.
        
      
    
  
